This Article supports SDG 3 by analysing several cohorts of people with HIV/HCV co-infection across 6 high-income countries, and identifying that a substantial proportion had not commenced direct-acting antiviral treatment for HCV infection despite unrestricted access. Factors associated with commencement or lack thereof are explored; for example, people with indicators of low engagement with HIV care (eg, not on antiretroviral therapy) were more likely not to have commenced HCV direct-acting antiviral treatment)
This study was designed to explore the relationship between Alzheimer's disease (AD) rates and socioeconomic conditions in 120 countries.
Drinking water and sanitation services in high-income countries typically bring widespread health and other benefits to their populations.
This paper applies stochastic process models (SPM) to study Alzheimer's disease (AD) using data on AD onset and longitudinal body mass index (BMI) trajectories, revealing that APOE e4 carriers are less resilient to deviations in BMI, with age-related declines in adaptive response and differences in allostatic load accumulation, thereby providing new insights into the connections between age, genetic factors, and risk factors in AD development and aging.
This review discusses the link between isolation, loneliness, and Alzheimer's Disease, and underscores the necessity of understanding and addressing these risk factors to develop successful prevention and treatment approaches.
Growing evidence suggests that the gut microbiome plays a crucial role in Alzheimer's disease (AD) pathogenesis through the microbiota-gut-brain axis, with alterations in gut microbiome composition linked to increased intestinal permeability, blood-brain barrier impairment, and neuroinflammation, and that gut microbiome modulation may alleviate AD symptoms, serve as a preventive measure, and also address comorbidities like Type 2 Diabetes Mellitus (T2DM), with future research directions including fecal microbiota transplantation (FMT) and precision medicine.
This review explores the potential therapeutic applications of the orexin system, focusing on its role as a target for treating various pathological conditions, including psychiatric and neurodegenerative diseases, and highlights the development of suvorexant as an orexin agent approved for insomnia treatment.
This article investigates the potential therapeutic effects of glutamic-oxaloacetic transaminase (GOT) in Alzheimer's disease (AD) by reducing glutamate concentrations in the hippocampi of mice, leading to improved neurological function, reduced β-amyloid protein levels, enhanced cognitive performance, increased neuron count and synaptic density, and altered protein expression, suggesting a promising treatment approach for early-stage AD.
This Article supports Sustainable Development Goal 3 by estimating the incidence and risk factors for vascular cognitive symptoms among first-ever stroke survivors in China, and shows an association of post-stroke cognitive impairment with age, education, and region (western China had higher rates of post-stroke cognitive impairment relative to other regions).
This Viewpoint supports Sustainable Development Goal 3 by discussing the effects of the FDA's approval of aducanumab, a treatment for early-stage Alzheimer's disease, despite its limited clinical benefit, as well as the decision of the Centers for Medicare and Medicaid Services to restrict coverage to individuals enrolled in clinical trials. The authors note that these decisions have led to a confusing landscape for patients with Alzheimer's disease.